HOTH Stock Summary and Trading Ideas (Hoth Therapeutics | NASDAQ:HOTH)

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Hoth Therapeutics trades on the NASDAQ stock market under the symbol HOTH.

As of March 30, 2026, HOTH stock price declined to $0.79 with 104,334 million shares trading.

HOTH has a beta of 1.07, meaning it tends to be more sensitive to market movements. HOTH has a correlation of 0.05 to the broad based SPY ETF.

HOTH has a market cap of $12.26 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HOTH traded as high as $4.30 and as low as $.58.

The top ETF exchange traded funds that HOTH belongs to (by Net Assets): VXF.

HOTH has underperformed the market in the last year with a price return of -21.0% while the SPY ETF gained +13.8%. HOTH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.8% and -23.3%, respectively, while the SPY returned -7.3% and -3.4%, respectively.

HOTH support price is $.77 and resistance is $.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOTH shares will trade within this expected range on the day.